Correlation of d-dimers to response to treatment in chronic spontaneous urticaria (UAS7 score): Results from the SUNRISE study

Objectives: Increased levels of blood d-dimers (D-D), the by-products of fibrin degradation, are linked to the severity of chronic spontaneous urticaria (CSU) and to poor response to antihistamines H1 (AH1). Omalizumab (OMA) is a human monoclonal anti–immunoglobulin E antibody registered as an add-on treatment of CSU in adults and adolescents (≥12 years old) with insufficient response to AH1. The SUNRISE study assessed the efficacy of Omalizumab on CSU symptoms and the correlation between D-D levels and response over time to treatment with OMA to explore its potential predictive value.